China Immunohistochemistry Market Size & Outlook
China immunohistochemistry market, 2018-2030 (US$M)
Related Markets
China immunohistochemistry market highlights
- The China immunohistochemistry market generated a revenue of USD 130.8 million in 2023 and is expected to reach USD 228.3 million by 2030.
- The China market is expected to grow at a CAGR of 8.3% from 2024 to 2030.
- In terms of segment, antibodies was the largest revenue generating product in 2023.
- Antibodies is the most lucrative product segment registering the fastest growth during the forecast period.
Immunohistochemistry market data book summary
| Market revenue in 2023 | USD 130.8 million |
| Market revenue in 2030 | USD 228.3 million |
| Growth rate | 8.3% (CAGR from 2023 to 2030) |
| Largest segment | Antibodies |
| Fastest growing segment | Antibodies |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antibodies, Reagents, Equipment, Kits |
| Key market players worldwide | Thermo Fisher Scientific Inc, Roche Holding AG, Merck KGaA, Danaher Corp, PerkinElmer, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Abcam PLC, Cell Signaling Technology, Bio SB |
Other key industry trends
- In terms of revenue, China accounted for 5.6% of the global immunohistochemistry market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan immunohistochemistry market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 228.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Immunohistochemistry Market Scope
Immunohistochemistry Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China immunohistochemistry market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunohistochemistry market will help companies and investors design strategic landscapes.
Antibodies was the largest segment with a revenue share of 41.51% in 2023. Horizon Databook has segmented the China immunohistochemistry market based on antibodies, reagents, equipment, kits covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing regulatory approvals and launch of novel IHC solutions are anticipated to support market growth in China. For instance, in October 2019, Agilent’s PD-L1 IHC 22C3 pharmDx assay was approved by National Medical Products Administration in China.
Furthermore, several emerging players are entering China by establishing their facilities in the region. In April 2018, Cell Signaling Technologies, Inc., an emerging player from the U.S., announced the opening of a new office in Shanghai, China.
This expansion was expected to strengthen its foothold in the Chinese market and boost its life sciences segment. Moreover, easy access to resources for development of advanced technology and products at economical costs has increased the number of local manufacturers of IHC antibodies, reagents, and instruments in the country.
Reasons to subscribe to China immunohistochemistry market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China immunohistochemistry market databook
-
Our clientele includes a mix of immunohistochemistry market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China immunohistochemistry market , including forecasts for subscribers. This country databook contains high-level insights into China immunohistochemistry market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China immunohistochemistry market size, by product, 2018-2030 (US$M)
China Immunohistochemistry Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
